0.8226
Precedente Chiudi:
$0.85
Aprire:
$0.8245
Volume 24 ore:
122.40K
Relative Volume:
0.27
Capitalizzazione di mercato:
$7.09M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+11.31%
1M Prestazione:
-48.07%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Metavia Inc Stock (MTVA) Company Profile
Nome
Metavia Inc
Settore
Industria
Telefono
(857) 702-9600
Indirizzo
545 CONCORD AVENUE, CAMBRIDGE
Confronta MTVA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MTVA
Metavia Inc
|
0.8226 | 7.09M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-30 | Iniziato | H.C. Wainwright | Buy |
Metavia Inc Borsa (MTVA) Ultime notizie
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PR Newswire
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider
MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan
Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX
MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World
MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research
Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz
MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com
MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Smart Shirt Might Predict Heart Problems - WFMZ.com
MetaVia reports positive obesity drug trial results - Investing.com Australia
MetaVia Announces Positive Phase 1 Trial Results - TipRanks
Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com
MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks
MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726 - StreetInsider
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss Without TitrationGame-Changing Trial Results - Stock Titan
Home-Delivered Medical Meals Could Prevent Millions Of Hospitalizations A Year - WFMZ.com
SCHD ETF News, 4/14/2025 - The Globe and Mail
MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance
MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN
Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView
FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World
Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks
MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus
MetaVia Inc. (MTVA) reports earnings - Quartz
Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV
Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire
Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV
New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV
Metavia Inc Azioni (MTVA) Dati Finanziari
Non sono disponibili dati finanziari per Metavia Inc (MTVA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):